In premarket trading, Athersys Inc. (ATHX) was up 10.64% at $1.56 and trading higher on the charts today. The Athersys share price fell -2.76 percent to close at $1.41 on Wednesday. A total of 1.24 million shares were traded, which is lower than the average volume over the last three months of 2.17 million. During the trading session, ATHX stock oscillated between $1.41 and $1.49. EPS ratio for ATHX was -0.45.
ATHX was down -2.08% over the last five sessions, down -15.57% over the past month, and down -19.43% since the beginning of the year. In the case of ATHX, its 50-day moving average is $1.6156 and its 200-day moving average is $1.8607. At the moment, ATHX’s RSI stands at 32.62. The ATHX stock is rising after a new publication decodes the multistem mechanism of the company.
What did that publication say?
Athersys is a biotechnology company dedicated to the discovery and development of new therapeutic products designed to extend and improve human life. Athx is developing its MultiStem cell therapy product, an adult-derived stem cell product that can be purchased off-the-shelf.
ATHX product is initially intended for use in cases of neurological, inflammatory, immune, cardiovascular, as well as other critical care conditions. There are also several trials evaluating this potential regenerative medicine product at ATHX. MultiStem cell therapy is being further developed toward commercialization with ATHX’s strategic partnerships and network of collaborations.
Today, Athersys announced that its data gathered from preclinical research for several years have been published in the peer-reviewed journal Scientific Reports.
- Multipotent Adult Progenitor Cells (MAPC), clinically called MultiStem (invimestrocel), was studied in four in vitro studies to examine how they modulate inflammatory responses.
- A possible mechanism by which ATHX’s MultiStem halts inflammatory organ injury and promotes recovery following tissue injury involves promoting endogenous, immunoregulatory mechanisms, including Treg differentiation, proliferation, and phenotypic activity.
- Athersys (ATHX) and its collaborators have published many scientific papers related to MAPC in recent years.
- The results complement previous reports on Treg induction in preclinical animal models and in human volunteers participating in ATHX’s clinical development programs.
Other developments around MultiStem:
According to Athersys (ATHX), its partner HEALIOS KK (Healios) has recently completed the enrollment in the ONE-BRIDGE study in Japan evaluating MultiStem (invimestrocel) in patients suffering from acute respiratory distress syndrome (ARDS). Two cohorts of patients are involved in the ONE-BRIDGE trial.
With cohort 1, ATHX’s MultiStem treatment will be evaluated for its safety and efficacy in patients suffering from pneumonia-induced ARDS. The objective of cohort 2 was to evaluate the safety of MultiStem treatment in five patients who had been induced ARDS by COVID-19. After analyzing the data, ATHX-partner Healios will make a subsequent announcement depending on the results, if desired.
